teysuno (15+4,35+11,8)mg/cap καψακιο, σκληρο
nordic group b.v., netherlands - tegafur, gimeracil, oteracil - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (15+4,35+11,8)mg/cap - 0017902237 - tegafur - 15.000000 mg; 0103766252 - gimeracil - 4.350000 mg; 002207752 - oteracil - 11.800000 mg - tegafur, combinations
teysuno (20+5,8+15,8)mg/cap καψακιο, σκληρο
nordic group b.v., netherlands - tegafur, gimeracil, oteracil - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (20+5,8+15,8)mg/cap - 0017902237 - tegafur - 20.000000 mg; 0103766252 - gimeracil - 5.800000 mg; 002207752 - oteracil - 15.800000 mg - tegafur, combinations
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - Νεοπλάσματα του στομάχου - Αντινεοπλασματικοί παράγοντες - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.
uft (100+224)mg/cap caps
merck a.e. - tegafur, combinations - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (100+224)mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
ftorafur 400mg/10ml inj.so.inf
ΝΕΛΕΤΑ Ε.Π.Ε. - tegafur - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ - 400mg/10ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
ftorafur 400mg/cap caps
ΝΕΛΕΤΑ Ε.Π.Ε. - tegafur - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 400mg/cap
teysuno (15+4,35+11,8)mg/cap caps
nordic group b.v., netherlands - tegafur, combinations - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (15+4,35+11,8)mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ
teysuno (20+5,8+15,8)mg/cap caps
nordic group b.v., netherlands - tegafur, combinations - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - (20+5,8+15,8)mg/cap - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ